CDI Revenue and Competitors
Estimated Revenue & Valuation
- CDI's estimated annual revenue is currently $15M per year.
- CDI's estimated revenue per employee is $7,236
Employee Data
- CDI has 2073 Employees.
- CDI grew their employee count by 24% last year.
CDI's People
Name | Title | Email/Phone |
---|
CDI Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $35M | 275 | 34% | N/A | N/A |
#2 | $15M | 427 | 30% | N/A | N/A |
#3 | $15M | 140 | 9% | N/A | N/A |
#4 | $750M | 25079 | 0% | N/A | N/A |
#5 | $15M | 86 | 2% | N/A | N/A |
#6 | $7.5M | 38 | -5% | N/A | N/A |
#7 | $7.5M | 145 | 15% | N/A | N/A |
#8 | $7.5M | 58 | 5% | N/A | N/A |
#9 | $7.5M | 103 | 2% | N/A | N/A |
#10 | $15M | 183 | 10% | N/A | N/A |
What Is CDI?
A non-profit organization present in 13 countries, that transforms lives and strengthens low-income communities by empowering people with ICTs.
keywords:N/AN/A
Total Funding
2073
Number of Employees
$15M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CDI News
2022-04-17 - CDI Full vs CDI Lite: What's new in Contexts and Dependency Injection 4.0
Previously, the CDI spec included a CDI Core part. That was the basis for the CDI SE and CDI EE implementations. But in 4.0, the CDI Core was...
2022-04-13 - Continuous Enteral Vancomycin Infusion in ICU Patients With ...
CDI is the leading cause of diarrhea in hospitalized patients and a significant health care-associated infection that is associated with a...
2022-04-06 - Continuous Enteral Vancomycin Helpful in Cases of Severe ...
Continuous enteral vancomycin can be an effective treatment patients with severe Clostridioides difficile infection (CDI), according to a...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 2074 | 9% | N/A |
#2 | $640.6M | 2080 | 0% | N/A |
#3 | $1029.4M | 2083 | -2% | N/A |
#4 | $380.4M | 2090 | N/A | N/A |
#5 | $790.4M | 2091 | -3% | N/A |